PMID- 25387821
OWN - NLM
STAT- MEDLINE
DCOM- 20160802
LR  - 20221207
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 31
IP  - 7
DP  - 2015 Oct
TI  - Impact of roux-en Y gastric bypass surgery on prognostic factors of type 2 
      diabetes mellitus: meta-analysis and systematic review.
PG  - 653-62
LID - 10.1002/dmrr.2622 [doi]
AB  - Our aim is to clarify the features of complete type 2 diabetes mellitus (T2DM) 
      remission in patients who undergo Roux-en Y gastric bypass surgery, to better 
      determine factors affecting the outcome of T2DM surgery. A search was conducted 
      for original studies on Medline, PubMed and Elsevier from inception until October 
      28, 2014. All of the articles included in this study were assessed with the 
      application of predetermined selection criteria and were divided into two groups: 
      Roux-en Y gastric bypass surgery for T2DM patients in remission or non-remission. 
      The meta-analysis results demonstrated that fasting C-peptide values were 
      significantly associated with increased remission (C-peptide: 95%CI = 0.2-1.0) 
      whereas T2DM duration, patient age, preoperative insulin use, preoperative 
      fasting blood glucose values and preoperative glycosylated haemoglobin values 
      were significantly associated with reduced remission (T2DM duration: 95%CI = -1.2 
      - -0.7; age: 95%CI = -0.5 - -0.1; percentage of preoperative insulin users: odd 
      ratio = 0.10, 95%CI = 0.07-0.15; preoperative fasting blood glucose: 95%CI = -0.9 
      - -0.5; preoperative glycosylated haemoglobin: 95%CI = -1.1 - -0.4). However, the 
      results demonstrated that body mass index was not statistically different (body 
      mass index: 95%CI = -0.2-0.6). The results of the systematic review demonstrated 
      that smaller waist circumference; lower total cholesterol, triglycerides and 
      low-density lipoprotein levels, increased higher high-density lipoprotein levels, 
      shorter cardiovascular disease history and less preoperative prevalence of 
      hypertension contribute to the increased postoperative remission rate. Better 
      results are obtained in younger patients with less severe diabetes, a smaller 
      waist circumference, higher preoperative high-density lipoprotein, lower 
      preoperative total cholesterol, triglycerides and low-density lipoprotein levels 
      and fewer other complications of shorter durations.
CI  - Copyright (c) 2014 John Wiley & Sons, Ltd.
FAU - Chen, Yali
AU  - Chen Y
AD  - The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, 
      China.
FAU - Zeng, Guangzheng
AU  - Zeng G
AD  - Department of Gastrointestinal Anal Surgery and Institute of Gastroenterology, 
      The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, 
      China.
FAU - Tan, Jingwang
AU  - Tan J
AD  - Chinese PLA General Hospital, Beijing, China.
FAU - Tang, Jun
AU  - Tang J
AD  - Jiangxi Provincial Tumor Hospital, Hospital Infection Branch, Nanchang, Jiangxi 
      Province, China.
FAU - Ma, Jingsheng
AU  - Ma J
AD  - Department of Gastrointestinal Anal Surgery and Institute of Gastroenterology, 
      The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, 
      China.
FAU - Rao, Benqiang
AU  - Rao B
AD  - Department of Gastrointestinal Anal Surgery and Institute of Gastroenterology, 
      The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20141217
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Age Factors
MH  - Blood Glucose/*metabolism
MH  - Body Mass Index
MH  - C-Peptide/*metabolism
MH  - Cholesterol/metabolism
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/*metabolism
MH  - *Gastric Bypass
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Hypertension/complications
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Lipoproteins, HDL/metabolism
MH  - Lipoproteins, LDL/metabolism
MH  - Obesity, Morbid/complications/*surgery
MH  - Prognosis
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Triglycerides/metabolism
OTO - NOTNLM
OT  - RYGB surgery
OT  - T2DM
OT  - prognostic factors
EDAT- 2014/11/13 06:00
MHDA- 2016/08/03 06:00
CRDT- 2014/11/13 06:00
PHST- 2014/04/29 00:00 [received]
PHST- 2014/10/26 00:00 [revised]
PHST- 2014/10/27 00:00 [accepted]
PHST- 2014/11/13 06:00 [entrez]
PHST- 2014/11/13 06:00 [pubmed]
PHST- 2016/08/03 06:00 [medline]
AID - 10.1002/dmrr.2622 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2015 Oct;31(7):653-62. doi: 10.1002/dmrr.2622. Epub 2014 
      Dec 17.